| Moderna Switzerland GmbH - Spikevax JN.1 (mRNA-1273.167), 0.10mg/ml, Dispersion zur Injektion | | 69788 | | 01 | | Spikevax JN.1 (mRNA-1273.167), 0.10mg/ml | | Dispersion zur Injektion | | J07BX | | Andere virale Impfstoffe | | 09.09.2024 | | |
| | Composition | | Suspension: SARS-CoV-2 JN.1 mRNA 50 µg pro dosi, heptadecan-9-ylis 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)-octanoas, cholesterolum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, 1,2-dimyristoyl-rac-glycero-3-polyethylenglycoli 2000 aether methylicus, trometamolum, trometamoli hydrochloridum, acidum aceticum, natrii acetas trihydricus, saccharum, aqua ad iniectabile, pro dosi, natrium 0.017 mg pro dosi. | | Packungsbestandteile | | Dispersion zur Injektion | | | | | | BAG: Principe actif | Concentr. |
|---|
| Sars-Cov-2 jn.1 Mrna | 50 mcg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| 1,2-dimyristoyl-Rac-Glycero-3-Polyethylenglycoli | 2000 | | | 1,2-distearoyl-Sn-Glycero-3-Phosphocholinum | | | | Acide Acétique | | | | Aether Methylicus | | | | Cholesterol | | | | Mrna | 50 µg | | | Sodium Acetate Trihydrate | | | | Sodium | 0.017 mg | | | Saccharumaqua | | | | Sars-Cov-2 jn. | 1 | Suspension | | Trometamoli Hydrochloridum | | | | Trometamol | | |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 001 | | 75.83 | 97.60 | B | LS | Non | | 002 | 10 | 758.30 | 828.30 | B | LS | Non |
|
|
